Understanding Diabetes: Types, Causes, and Comprehensive Management Strategies

What Is Diabetes?

Diabetes mellitus encompasses a group of metabolic disorders defined by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Over time, persistently elevated blood glucose damages blood vessels and nerves, leading to complications affecting the eyes, kidneys, nerves, heart, and blood vessels.

Classification of Diabetes

Type 1 Diabetes (5–10% of Cases)

  • Pathophysiology: Autoimmune destruction of pancreatic β-cells leads to absolute insulin deficiency.
  • Onset: Typically diagnosed in childhood or adolescence, though it can occur at any age (LADA — latent autoimmune diabetes in adults — presents later in life).
  • Treatment: Lifelong exogenous insulin therapy via multiple daily injections (basal-bolus) or insulin pump.
  • Risk Factors: HLA-DR3/DR4 genotypes, family history, and potential viral triggers.

Type 2 Diabetes (90–95% of Cases)

  • Pathophysiology: Insulin resistance combined with progressive β-cell failure results in relative insulin deficiency.
  • Risk Factors: Strong interplay of genetics and lifestyle — obesity, physical inactivity, poor diet, and aging.
  • Management: Lifestyle modification, oral agents, GLP-1 receptor agonists, and insulin as needed.

Other Specific Types

  • Gestational Diabetes (GDM): Hyperglycemia first recognized during pregnancy; significantly increases future risk of type 2 diabetes.
  • Monogenic Diabetes (MODY, Neonatal): Caused by single-gene defects (e.g., HNF1A, GCK); genetic diagnosis guides targeted treatment.
  • Pancreatogenic (Type 3c) Diabetes: Results from pancreatitis, pancreatic resection, cystic fibrosis, or hemochromatosis.
  • Drug-Induced Diabetes: Associated with glucocorticoids, antipsychotics, protease inhibitors, and tyrosine kinase inhibitors.

Diagnostic Criteria (ADA Guidelines)

TestNormalPrediabetesDiabetes
Fasting Plasma Glucose<100 mg/dL100–125 mg/dL≥126 mg/dL
2-hr OGTT (75g)<140 mg/dL140–199 mg/dL≥200 mg/dL
HbA1c<5.7%5.7–6.4%≥6.5%
Random Plasma Glucose + Symptoms——≥200 mg/dL

Diagnosis requires confirmation with repeat testing unless unequivocal hyperglycemia with classic symptoms is present.

Four Pillars of Diabetes Management

1. Lifestyle Therapy (Foundation for All Types)

  • Medical Nutrition Therapy: Individualized, registered dietitian-led plans emphasizing Mediterranean, DASH, or plant-based eating patterns.
  • Carbohydrate Management: Consistent carbohydrate intake, fiber ≥25–30 g/day, limited added sugars and refined grains.
  • Physical Activity: ≥150 minutes/week moderate aerobic exercise plus 2–3 resistance training sessions.
  • Weight Management: 5–7% body weight loss dramatically improves insulin sensitivity.
  • Sleep & Stress: 7–9 hours sleep nightly; stress reduction; smoking cessation.

2. Pharmacotherapy for Type 2 Diabetes

  • Metformin: First-line unless contraindicated; reduces hepatic glucose output and improves insulin sensitivity.
  • GLP-1 Receptor Agonists (semaglutide, tirzepatide, liraglutide): Glucose-dependent insulin secretion, glucagon suppression, appetite reduction, weight loss, cardiovascular and renal benefits.
  • SGLT2 Inhibitors (empagliflozin, dapagliflozin): Promote glucosuria; reduce weight and blood pressure; provide cardiovascular and renal protection.
  • Other Oral Agents: DPP-4 inhibitors, thiazolidinediones, sulfonylureas, glinides, α-glucosidase inhibitors — used as alternatives or adjuncts.
  • Insulin Therapy: Basal → basal-bolus → pump progression when oral agents are insufficient.

3. Type 1 Diabetes–Specific Management

  • Basal-bolus regimen (multiple daily injections) or continuous subcutaneous insulin infusion (insulin pump).
  • Continuous glucose monitoring (CGM) is now standard of care.
  • Automated insulin delivery (hybrid closed-loop) systems.
  • Carbohydrate counting, insulin-to-carbohydrate ratios, and correction factors.

4. Monitoring & Glycemic Targets

  • Glucose Monitoring: SMBG or CGM targeting Time in Range (70–180 mg/dL) >70%; time below 54 mg/dL <1%.
  • HbA1c: Individualized target <7% (range 6.5–8% based on patient factors).
  • Cardiometabolic Targets: BP <130/80 mmHg; LDL <70 mg/dL (ASCVD) or <100 mg/dL; statin therapy per risk category.
  • Annual Screenings: Dilated eye exam, comprehensive foot exam, urine albumin-to-creatinine ratio, eGFR, lipid panel.

Complications

  • Microvascular: Retinopathy, nephropathy, neuropathy.
  • Macrovascular: Coronary artery disease, stroke, peripheral artery disease — 2–4× higher risk.
  • Acute Complications: Diabetic ketoacidosis (type 1), hyperosmolar hyperglycemic state (type 2), severe hypoglycemia.
  • Other: Increased infection risk, non-alcoholic fatty liver disease, cognitive decline, elevated cancer risk.

Type 2 Diabetes Prevention

  • Landmark Trials (DPP/DPS): Intensive lifestyle intervention (7% weight loss + 150 min/week activity) reduced incidence by 58%.
  • Metformin: 31% reduction in high-risk prediabetes.
  • Screening: Begin at age 35 or earlier with risk factors (ADA recommendation).

Diabetes - Related Articles